Group 1 - The core point of the article is that Qianxin Bio-B (02509.HK) has entered into a licensing and collaboration agreement with Windward BioGroup AG's subsidiary LE2025 Therapeutics AG, granting LE2025 exclusive rights to develop and commercialize QX027N in specified regions outside of mainland China, Taiwan, Hong Kong, and Macau [1] - The agreement allows Qianxin Bio to receive up to $700 million in total payments, which includes an upfront payment, equity from Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in the licensed regions [1] Group 2 - Windward Bio is a clinical-stage biotechnology company with expertise in discovery, development, and commercialization, focused on transforming treatment for patients with advanced immune diseases [2] - Windward Bio's leading project is WIN378, a potential best-in-class long-acting anti-TSLP monoclonal antibody currently undergoing Phase II clinical trials for asthma [2] - The company's research pipeline also includes WIN027, a long-acting dual-specific antibody targeting TSLP and IL-13, which has potential applications across various immune diseases [2]
荃信生物-B(02509.HK)与Windward Bio子公司达成QX027N许可合作 总对价可达7亿美元